Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

411 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of chemotherapy after progression during or following PARPi exposure in ovarian cancer.
Xu-Vuillard A, Guerin-Charbonnel C, Bocquet F, Cheeseman S, Kubelac PM, Zenatri M, Hall G, Achimas-Cadariu P, Hanvic B, Fenton H, Sturz-Lazăr AM, Augereau P, Ray-Coquard I, Leary A, Frenel JS. Xu-Vuillard A, et al. Among authors: leary a. ESMO Open. 2024 Sep;9(9):103694. doi: 10.1016/j.esmoop.2024.103694. Epub 2024 Sep 3. ESMO Open. 2024. PMID: 39232440 Free PMC article.
Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer.
Kubelac P, Genestie C, Auguste A, Mesnage S, Le Formal A, Pautier P, Gouy S, Morice P, Bentivegna E, Maulard A, Adam J, Achimas-Cadariu P, Leary A. Kubelac P, et al. Among authors: leary a. Cancers (Basel). 2020 Mar 17;12(3):707. doi: 10.3390/cancers12030707. Cancers (Basel). 2020. PMID: 32192091 Free PMC article.
Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinoma.
Colomba E, Alexandre J, Le Teuff G, Genestie C, Coupez D, Coquard IR, Brachet PE, de Percin S, Sajous C, Fabbro M, Delanoy N, Joly F, Frenel JS, Pautier P, Leary A. Colomba E, et al. Among authors: leary a. Gynecol Oncol. 2023 Feb;169:78-84. doi: 10.1016/j.ygyno.2022.11.029. Epub 2022 Dec 13. Gynecol Oncol. 2023. PMID: 36521352
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.
Kurtz JE, Pujade-Lauraine E, Oaknin A, Belin L, Leitner K, Cibula D, Denys H, Rosengarten O, Rodrigues M, de Gregorio N, Martinez García J, Petru E, Kocián R, Vergote I, Pautier P, Schmalfeldt B, Gaba L, Polterauer S, Mouret Reynier MA, Sehouli J, Churruca C, Selle F, Joly F, D'Hondt V, Bultot-Boissier É, Lebreton C, Lotz JP, Largillier R, Heudel PE, Heitz F; ATALANTE/ENGOT-ov29 Investigators. Kurtz JE, et al. J Clin Oncol. 2023 Oct 20;41(30):4768-4778. doi: 10.1200/JCO.23.00529. Epub 2023 Aug 29. J Clin Oncol. 2023. PMID: 37643382 Free PMC article. Clinical Trial.
Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial.
Azaïs H, Brochard C, Taly V, Benoit L, Ferron G, Ray-Coquard I, You B, Abadie-Lacourtoisie S, Lebreton C, Venat L, Louvet C, Favier L, Blonz C, Dohollou N, Malaurie E, Dubot C, Kurtz JE, Pujade-Lauraine E, Rouleau E, Leary A, Bats AS, Blons H, Laurent-Puig P. Azaïs H, et al. Among authors: leary a. Gynecol Oncol. 2024 Dec 12;192:145-154. doi: 10.1016/j.ygyno.2024.12.004. Online ahead of print. Gynecol Oncol. 2024. PMID: 39671779 Free article.
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib.
Barnicle A, Ray-Coquard I, Rouleau E, Cadoo K, Simpkins F, Aghajanian C, Leary A, Poveda A, Lheureux S, Pujade-Lauraine E, You B, Ledermann J, Matulonis U, Gourley C, Timms KM, Lai Z, Hodgson DR, Elks CE, Dearden S, Egile C, Lao-Sirieix P, Harrington EA, Brown JS. Barnicle A, et al. Among authors: leary a. Genome Med. 2024 Dec 18;16(1):145. doi: 10.1186/s13073-024-01413-5. Genome Med. 2024. PMID: 39695768 Free PMC article.
Rucaparib in the landscape of PARP inhibition in ovarian cancer.
Colomba E, Pautier P, Pommeret F, Leary A. Colomba E, et al. Among authors: leary a. Expert Rev Anticancer Ther. 2019 Jun;19(6):437-446. doi: 10.1080/14737140.2019.1607302. Epub 2019 May 16. Expert Rev Anticancer Ther. 2019. PMID: 30977683 Review.
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes.
Haggstrom L, Lee YC, Scott C, Harter P, Woelber L, Ledermann J, Gourley C, McNeish IA, Amant F, Ray-Coquard I, Leary A, Oza AM, Tinker A, González Martin A, Cecere SC, Pignata S, Colombo N, Yoshida H, Marth C, Rosengarten O, Moore KN, Gómez-García EM, Tan D, Friedlander ML. Haggstrom L, et al. Among authors: leary a. Int J Gynecol Cancer. 2024 Dec 2;34(12):1932-1939. doi: 10.1136/ijgc-2024-005976. Int J Gynecol Cancer. 2024. PMID: 39438068
411 results